Meningococcal Group B Vaccine 3 strain

Meningococcal Group B Vaccine 3 strain Brand Name– BEXSERO

What is Meningococcal Group B Vaccine 3 strain

There are 4 different formulations of meningococcal vaccines available: meningococcal polysaccharide vaccine (Menomune); meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Menactra); meningococcal oligosaccharide diphtheria toxoid conjugate vaccine (Menveo); meningococcal recombinant vaccine (Trumenba and Bexsero).

All four vaccines are indicated for the prevention of invasive disease caused by Neisseria meningitis, but they do not all cover the same serogroups.

Prior to prescription or administration, confirm which specific vaccine is desired. Menomune, Menactra, and Menveo are active against serogroups A, C, Y, and W-135, while Trumenba and Bexsero are active against serogroup B.

For additional information on other meningococcal vaccines, see Meningococcal Polysaccharide Vaccine (MPSV4), Meningococcal Conjugate Vaccine (MCV4), or Meningococcal Group B Vaccine (4 strain) content.

Indications

  • meningococcal infection prophylaxis

Side Effects

  1. anaphylactoid reactions
  2. arthralgia
  3. erythema
  4. fatigue
  5. fever
  6. headache
  7. injection site reaction
  8. myalgia
  9. nausea
  10. pharyngitis
  11. rash
  12. syncope

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • activities requiring coordination and concentration
  • agammaglobulinemia
  • anticoagulant therapy
  • breast-feeding
  • chemotherapy
  • children
  • coagulopathy
  • corticosteroid therapy
  • fever
  • geriatric
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • hypogammaglobulinemia
  • immunosuppression
  • infants
  • infection
  • latex hypersensitivity
  • neonates
  • neoplastic disease
  • pregnancy
  • radiation therapy
  • severe combined immunodeficiency (SCID)
  • thrombocytopenia
  • vitamin K deficiency

Interactions

  • Ocrelizumab
  • Siponimod